{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T14:39:24Z","timestamp":1791383964290,"version":"4.3.3"},"reference-count":32,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:00:00Z","timestamp":1758499200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020439","name":"Jiangsu Pharmaceutical Association","doi-asserted-by":"publisher","award":["No. H202311"],"award-info":[{"award-number":["No. H202311"]}],"id":[{"id":"10.13039\/100020439","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Purpose<\/jats:title>\n<jats:p>Excessive daytime sleepiness (EDS) seriously affects quality of life and may increase the risk of life-threatening situations, such as motor vehicle accidents. Solriamfetol is a novel medication approved for the treatment of EDS and serves as an alternative to traditional stimulants. This retrospective pharmacovigilance study aimed to analyze adverse events (AEs) related to solriamfetol based on real-world data.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>Data regarding solriamfetol-related adverse events were retrieved from the FDA Adverse Event Reporting System (FAERS) from Q3 of 2019 to Q1 of 2024. A total of 1550 reports on solriamfetol-related AEs were analyzed using disproportionality analysis to identify AE signals across various organ systems.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>A large proportion of AEs were reported among female patients (64.06%), primarily including those with narcolepsy (38.13%) and obstructive sleep apnea (3.68%). The most frequently reported AEs included headache, anxiety, and drug ineffectiveness, with 46.8% of AEs occurring within 7 days of treatment initiation. Furthermore, solriamfetol was significantly associated with psychiatric and nervous system disorders as well as cardiac and general disorders.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Solriamfetol-related adverse events were mainly psychiatric, neurological, cardiac, and general disorders, with headache, anxiety, and drug ineffectiveness being the most common. Nearly half of the events occurred within the first week of treatment. Given the limitations of the FAERS database, further prospective studies are needed to confirm these findings.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0333130","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T17:28:36Z","timestamp":1758562116000},"page":"e0333130","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Post-marketing safety of solriamfetol: A retrospective pharmacovigilance study based on the us food and drug administration adverse event reporting system"],"prefix":"10.1371","volume":"20","author":[{"given":"Lingling","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4291-6295","authenticated-orcid":true,"given":"Kaijian","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,9,22]]},"reference":[{"issue":"10357","key":"pone.0333130.ref001","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(22)01018-2","article-title":"Understanding and approaching excessive daytime sleepiness","volume":"400","author":"L P\u00e9rez-Carbonell","year":"2022","journal-title":"Lancet"},{"key":"pone.0333130.ref002","doi-asserted-by":"crossref","first-page":"101306","DOI":"10.1016\/j.smrv.2020.101306","article-title":"Diagnosis of central disorders of hypersomnolence: A reappraisal by European experts","volume":"52","author":"GJ Lammers","year":"2020","journal-title":"Sleep Med Rev"},{"key":"pone.0333130.ref003","article-title":"An approach to excessive daytime sleepiness in adults","volume":"368","author":"J Brown","year":"2020","journal-title":"BMJ"},{"issue":"3","key":"pone.0333130.ref004","doi-asserted-by":"crossref","DOI":"10.1093\/sleep\/zsz249","article-title":"Natural history of excessive daytime sleepiness: a population-based 5-year longitudinal study","volume":"43","author":"I Jaussent","year":"2020","journal-title":"Sleep"},{"key":"pone.0333130.ref005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.sleep.2018.08.028","article-title":"Excessive daytime sleepiness among children and adolescents: prevalence, correlates, and pubertal effects","volume":"53","author":"Y Liu","year":"2019","journal-title":"Sleep Med"},{"issue":"1","key":"pone.0333130.ref006","first-page":"65","article-title":"A Comprehensive Review of Solriamfetol to Treat Excessive Daytime Sleepiness","volume":"54","author":"MC Fuller","year":"2024","journal-title":"Psychopharmacol Bull"},{"issue":"2","key":"pone.0333130.ref007","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/joim.13294","article-title":"Excessive daytime sleepiness, morning tiredness and major adverse cardiovascular events in patients with chronic coronary syndrome","volume":"290","author":"M Olszowka","year":"2021","journal-title":"J Intern Med"},{"key":"pone.0333130.ref008","first-page":"4215938","article-title":"A Practical Approach to Excessive Daytime Sleepiness: A Focused Review","volume":"2016","author":"BJ Murray","year":"2016","journal-title":"Can Respir J"},{"issue":"3","key":"pone.0333130.ref009","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jsmc.2022.06.012","article-title":"Pharmacologic Management of Excessive Daytime Sleepiness","volume":"17","author":"T Ono","year":"2022","journal-title":"Sleep Med Clin"},{"issue":"5","key":"pone.0333130.ref010","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1513\/AnnalsATS.202006-696FR","article-title":"Excessive Daytime Sleepiness in Obstructive Sleep Apnea. Mechanisms and Clinical Management","volume":"18","author":"C Lal","year":"2021","journal-title":"Ann Am Thorac Soc"},{"issue":"2","key":"pone.0333130.ref011","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jsmc.2020.02.006","article-title":"Pharmacologic Management of Excessive Daytime Sleepiness","volume":"15","author":"S Takenoshita","year":"2020","journal-title":"Sleep Med Clin"},{"issue":"4","key":"pone.0333130.ref012","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s13311-012-0150-9","article-title":"A practical guide to the therapy of narcolepsy and hypersomnia syndromes","volume":"9","author":"EJM Mignot","year":"2012","journal-title":"Neurotherapeutics"},{"issue":"12","key":"pone.0333130.ref013","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1080\/17476348.2018.1541742","article-title":"Solriamfetol for the treatment of daytime sleepiness in obstructive sleep apnea","volume":"12","author":"VC Abad","year":"2018","journal-title":"Expert Rev Respir Med"},{"issue":"8","key":"pone.0333130.ref014","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1080\/17512433.2019.1632705","article-title":"Solriamfetol for the treatment of excessive daytime sleepiness associated with narcolepsy","volume":"12","author":"J Yang","year":"2019","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"2","key":"pone.0333130.ref015","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.clinthera.2018.12.001","article-title":"A Phase I, Randomized, Crossover, Open-label Study of the Pharmacokinetics of Solriamfetol (JZP-110) in Healthy Adult Subjects With and Without Food","volume":"41","author":"K Zomorodi","year":"2019","journal-title":"Clin Ther"},{"issue":"12","key":"pone.0333130.ref016","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1177\/0269881118796814","article-title":"A randomized, double-blind, placebo-controlled, crossover study to evaluate the human abuse liability of solriamfetol, a selective dopamine and norepinephrine reuptake inhibitor","volume":"32","author":"LP Carter","year":"2018","journal-title":"J Psychopharmacol"},{"issue":"3","key":"pone.0333130.ref017","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/ana.25423","article-title":"A randomized study of solriamfetol for excessive sleepiness in narcolepsy","volume":"85","author":"MJ Thorpy","year":"2019","journal-title":"Ann Neurol"},{"issue":"1","key":"pone.0333130.ref018","doi-asserted-by":"crossref","first-page":"11262","DOI":"10.1038\/s41598-024-62129-5","article-title":"Data mining and safety analysis of avatrombopag: a retrospective pharmacovigilance study based on the US food and drug administration\u2019s adverse event reporting system","volume":"14","author":"H Zhu","year":"2024","journal-title":"Sci Rep"},{"key":"pone.0333130.ref019","doi-asserted-by":"crossref","first-page":"1338902","DOI":"10.3389\/fphar.2024.1338902","article-title":"Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database","volume":"15","author":"F Zou","year":"2024","journal-title":"Front Pharmacol"},{"key":"pone.0333130.ref020","doi-asserted-by":"crossref","first-page":"1436405","DOI":"10.3389\/fphar.2024.1436405","article-title":"Data mining and safety analysis of dual orexin receptor antagonists (DORAs): a real-world pharmacovigilance study based on the FAERS database","volume":"15","author":"M Jiang","year":"2024","journal-title":"Front Pharmacol"},{"key":"pone.0333130.ref021","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.sleep.2023.01.022","article-title":"Solriamfetol real world experience study (SURWEY): Initiation, titration, safety, effectiveness, and experience during follow-up for patients with narcolepsy from Germany","volume":"103","author":"Y Winter","year":"2023","journal-title":"Sleep Med"},{"issue":"3","key":"pone.0333130.ref022","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2165\/00003088-200948030-00001","article-title":"Sex differences in pharmacokinetics and pharmacodynamics","volume":"48","author":"OP Soldin","year":"2009","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"pone.0333130.ref023","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/s41582-019-0226-9","article-title":"Narcolepsy - clinical spectrum, aetiopathophysiology, diagnosis and treatment","volume":"15","author":"CLA Bassetti","year":"2019","journal-title":"Nat Rev Neurol"},{"issue":"5","key":"pone.0333130.ref024","article-title":"Solriamfetol for the Use of Narcolepsy: A Systematic Review","volume":"14","author":"A Iturburu","year":"2022","journal-title":"Cureus"},{"issue":"7","key":"pone.0333130.ref025","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.5665\/sleep.5968","article-title":"Effect of Oral JZP-110 (ADX-N05) on Wakefulness and Sleepiness in Adults with Narcolepsy: A Phase 2b Study","volume":"39","author":"C Ruoff","year":"2016","journal-title":"Sleep"},{"issue":"10","key":"pone.0333130.ref026","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1177\/1060028020915537","article-title":"Solriamfetol for Excessive Sleepiness in Narcolepsy and Obstructive Sleep Apnea","volume":"54","author":"J Powell","year":"2020","journal-title":"Ann Pharmacother"},{"issue":"1","key":"pone.0333130.ref027","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1017\/S0033291721004979","article-title":"Attention-deficit\/hyperactivity disorder, headache and caffeine","volume":"52","author":"B Musafia","year":"2022","journal-title":"Psychol Med"},{"issue":"2","key":"pone.0333130.ref028","doi-asserted-by":"crossref","DOI":"10.1093\/sleep\/zsz220","article-title":"Long-term study of the safety and maintenance of efficacy of solriamfetol (JZP-110) in the treatment of excessive sleepiness in participants with narcolepsy or obstructive sleep apnea","volume":"43","author":"A Malhotra","year":"2020","journal-title":"Sleep"},{"key":"pone.0333130.ref029","unstructured":"Agency EM. Sunosi (international non-proprietary name solriamfetol): EU assessment report. 2019 [cited 6 Sep 2023]. Available from:https:\/\/wwwemaeuropaeu\/en\/medicines\/human\/EPAR\/sunosi"},{"issue":"11","key":"pone.0333130.ref030","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1007\/s11886-022-01786-2","article-title":"Long-COVID Syndrome and the Cardiovascular System: A Review of Neurocardiologic Effects on Multiple Systems","volume":"24","author":"NL DePace","year":"2022","journal-title":"Curr Cardiol Rep"},{"key":"pone.0333130.ref031","unstructured":"Ltd TPE. Sunosi (solriamfetol) flm-coated tablets: EU summary of product characteristics. 2022 [cited 6 Sep 2023].Available from:https:\/\/wwwemaeuropaeu\/en\/medicines\/human\/EPAR\/sunosi"},{"key":"pone.0333130.ref032","unstructured":"Inc AT. Sunosi (solriamfetol) tablets, for oral use: US prescribing information. 2023 [cited 6 Sep 2023]. Available from:https:\/\/wwwfdagov\/"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0333130","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T17:28:47Z","timestamp":1758562127000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0333130"}},"subtitle":[],"editor":[{"given":"Christian","family":"Veauthier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,9,22]]},"references-count":32,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9,22]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0333130","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,22]]}}}